{"url_path":"/sec/tvtx/8-k/2026-05-21/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000046-index.html","accession_number":"0001438533-26-000046","cik":"0001438533","ticker":"TVTX","issuer_name":"Travere Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000046-index.html","primary_entity_key":"0001438533","primary_entity_name":"Travere Therapeutics, Inc."},"word_count":367,"has_tables":true,"body_markdown":"Item 5.07     Submission of Matters to a Vote of Security Holders.\n\nOn May 19, 2026, the Company held the Annual Meeting. As of March 23, 2026, the record date for the Annual Meeting, 92,369,812 shares of common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 81,108,473 shares of common stock were present in person or represented by proxy for the five proposals summarized below.\n\nProposal 1: Election of Directors\n\nThe Company’s stockholders elected the ten persons listed below to serve until the Company’s 2027 Annual Meeting of Stockholders. The final voting results are as follows:\n\n Votes For Votes Withheld Broker Non-Votes\n\nRoy D. Baynes, M.D., Ph.D.66,479,9999,338,1495,290,327\n\nSuzanne Bruhn, Ph.D.74,711,9941,106,1545,290,327\n\nTimothy Coughlin73,695,9652,122,1835,290,327\n\nEric Dube, Ph.D.75,095,860722,2885,290,327\n\nGary Lyons74,208,9521,609,1965,290,327\n\nJeffrey Meckler73,469,2632,348,8855,290,327\n\nJohn A. Orwin74,657,4721,160,6765,290,327\n\nSandra Poole74,551,1381,267,0105,290,327\n\nRon Squarer74,767,4551,050,6935,290,327\n\nRuth Williams-Brinkley74,764,6791,053,4695,290,327\n\nProposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended\n\nThe Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000. The final voting results are as follows:\n\nVotes For 72,998,395\n\nVotes Against 2,787,402\n\nAbstentions 32,347\n\nBroker Non-Votes 5,290,327\n\nProposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers\n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results are as follows:\n\nVotes For 73,711,670\n\nVotes Against 2,073,324\n\nAbstentions 33,152\n\nBroker Non-Votes 5,290,327\n\nProposal 4: Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers\n\nThe Company’s stockholders indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows:\n\nOne Year 75,003,558\n\nTwo Years 4,996\n\nThree Years 766,756\n\nAbstentions42,836\n\nBroker Non-Votes 5,290,327\n\nProposal 5: Ratification of the Selection of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\nVotes For 80,708,265\n\nVotes Against 120,699\n\nAbstentions 279,509\n\nBroker Non-Votes —"}